These results indicate that SCFA treatment significantly alleviates MPTP-induced motor and anxiety-like deficits in mice, whereas DHK pretreatment partially reverses these beneficial effects, suggesting that EAAT2 activity is essential for the neuroprotective actions of SCFAs. The gene discussed is SLC1A2; the disease is Anxiety.